Coumermycin-induced dimerization of GyrB-containing fusion proteins.
Farrar
M A
MA
Merck Research Laboratories, Rahway, New Jersey 07065-0900, USA.
Olson
S H
SH
Perlmutter
R M
RM
D049933:Aminocoumarins; D000818:Animals; D002460:Cell Line; D003374:Coumarins / Q000494:pharmacology*; D027081:DNA Gyrase; D004250:DNA Topoisomerases, Type II / Q000737:chemistry* / Q000378:metabolism*; D019281:Dimerization; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D008958:Models, Molecular; D009675:Novobiocin / Q000494:pharmacology; D011993:Recombinant Fusion Proteins / Q000737:chemistry* / Q000378:metabolism; D015398:Signal Transduction
D049933:Aminocoumarins; D003374:Coumarins; D004791:Enzyme Inhibitors; D011993:Recombinant Fusion Proteins; D009675:Novobiocin; D027081:DNA Gyrase; D004250:DNA Topoisomerases, Type II; C004628:coumermycin